Cardinal Health Updates FY25 Outlook and FY26 Guidance

Cardinal Health ( (CAH) ) has issued an announcement.

On June 12, 2025, Cardinal Health announced updates to its fiscal year 2025 outlook and preliminary guidance for 2026, highlighting strategic initiatives and financial targets at its Investor Day. The company raised its non-GAAP diluted EPS guidance for FY25 and set preliminary FY26 guidance, emphasizing growth in Pharmaceutical and Specialty Solutions and other segments. Cardinal Health is investing in its Specialty Alliance MSO platform and expanding its Biopharma Solutions, while also enhancing its pharmaceutical distribution network with new facilities and technologies. The company aims to achieve sustainable long-term growth and value creation, with expectations of significant cash flow and share repurchases.

The most recent analyst rating on (CAH) stock is a Hold with a $104.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.

Spark’s Take on CAH Stock

According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.

Cardinal Health demonstrates strong revenue growth and operational efficiency, supported by positive earnings call highlights. However, the negative equity and overvaluation concerns limit its stock score. The technical analysis suggests bullish momentum, though overbought conditions could warrant caution. The strategic appointments and acquisitions provide long-term growth potential.

To see Spark’s full report on CAH stock, click here.

More about Cardinal Health

Cardinal Health operates in the healthcare industry, providing pharmaceutical and medical products and services. The company focuses on pharmaceutical distribution, specialty solutions, and medical products, with a market emphasis on enhancing healthcare delivery and efficiency.

Average Trading Volume: 2,420,006

Technical Sentiment Signal: Buy

Current Market Cap: $36.54B

See more data about CAH stock on TipRanks’ Stock Analysis page.